Notes: December 15, 2022 -- The Board approved a one-for-forty five reverse stock split of the Company’s issued and outstanding common stock (the “Reverse Stock Split”). On December 21, 2022, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split. The Reverse Stock Split will become effective as of 12:01 a.m. Eastern Time on December 22, 2022, and the Company’s common stock will begin trading on a split-adjusted basis when the market opens on December 22, 2022.The new CUSIP number for the common stock following the Reverse Stock Split will be 88362L209. <p> Oct. 31, 2019 -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing for regenerative medicine, today announced that the company will change its name to ThermoGenesis Holdings, Inc. (“ThermoGenesis”) in order to better reflect its new strategic focus on becoming a key solution provider for cell manufacturing tools and services in the cell and gene therapy markets. In conjunction with the name change, the company will begin trading under the new Nasdaq ticker symbol, THMO, effective Friday, November 1, 2019. In addition, the company’s common stock will trade under a new CUSIP number, 88362L100, beginning on Friday, November 1, 2019. <p> March 7, 2016. -- Cesca Therapeutics Inc. (KOOL) will effect a one-for-twenty (1-20) reverse split of its common stock. The CUSIP number will change to 157131202._______________February 19, 2014 -- Cesca Therapeutics Inc. (f/n/a ThermoGenesis Corp.) (NASDAQ: KOOL) today announced that it consummated the merger with TotipotentRX Corporation (for approximately 12,490,800 shares of the Company's common stock, as contemplated by the previously announced Agreement and Plan of Reorganization. Further, to reflect the surviving company's combined strength, the Company changed its name to Cesca Therapeutics Inc. Cesca stands for Clinical Excellence in Stem Cell Applications. The Company is expected to begin trading on Nasdaq as Cesca Therapeutics Inc. on Thursday, February 20, 2014. The Company will continue to trade under the Nasdaq ticker symbol KOOL.